Enveric Biosciences (ENVB) Free Cash Flow Growth (5y) (2015 - 2026)
Enveric Biosciences (ENVB) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.52% |
| Dec 31, 2025 | 4.53% |
| Sep 30, 2025 | -39.00% |
| Jun 30, 2025 | -40.30% |
| Mar 31, 2025 | -20.60% |
| Dec 31, 2024 | -29.94% |
| Jun 30, 2024 | -41.70% |
| Mar 31, 2024 | -21.14% |
| Dec 31, 2023 | -12.19% |
| Sep 30, 2023 | -16.43% |
| Jun 30, 2023 | -95.90% |
| Mar 31, 2023 | -62.09% |
| Dec 31, 2022 | -29.88% |
| Sep 30, 2022 | -115.38% |
| Jun 30, 2022 | -40.07% |
| Mar 31, 2022 | -42.89% |
| Dec 31, 2021 | -6.30% |
| Sep 30, 2021 | -42.79% |
| Jun 30, 2021 | -44.76% |
| Mar 31, 2021 | -171.93% |